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Abstract
Evidence of bias of self-reported smoking cessation during pregnancy is reported in high-income 
countries but not elsewhere. We sought to evaluate self-reported smoking cessation during 
pregnancy using biochemical verification and to compare characteristics of women with and 
without biochemically confirmed cessation in Argentina and Uruguay. In a cross-sectional study 
from October 2011 to May 2012, women who attended one of 21 prenatal clinics and delivered at 
selected hospitals in Buenos Aires, Argentina and Montevideo, Uruguay, were surveyed about 
their smoking cessation during pregnancy. We tested saliva collected from women <12 h after 
delivery for cotinine to evaluate self-reported smoking cessation during pregnancy. Overall, 
10.0% (44/441) of women who self-reported smoking cessation during pregnancy had 
biochemical evidence of continued smoking. Women who reported quitting later in pregnancy had 
a higher percentage of nondisclosure (17.2%) than women who reported quitting when learning of 
their pregnancy (6.4%).
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Smoking is the leading cause of preventable death among women and a leading preventable 
cause of poor pregnancy and infant outcomes in high-income countries (1). Self-reported 
smoking during pregnancy in nine countries in Latin America, Asia, and Africa was highest 
in two countries, Uruguay (18.3%) and Argentina (10.3%) (2). Studies in high-income 
countries have found that women’s self-reported smoking status during pregnancy can 
underestimate smoking prevalence by 24– 28%, and intervention studies have documented 
differences in self-reported and biochemically verified quitting (3,4). To our knowledge, no 
studies have been conducted to assess the prevalence of nondisclosure during pregnancy in 
middle-income countries, and prior studies have not assessed nondisclosure by women who 
spontaneously quit when learning of their pregnancy vs. later in pregnancy.
The objective of this study was to evaluate self-reported smoking cessation during 
pregnancy using biochemical verification among women attending 21 prenatal clinic 
clusters in Argentina and Uruguay. We sought to assess what percentage of women who 
self-reported quitting during pregnancy had evidence of current smoking. We also assessed 
differences in characteristics of women who were biochemically confirmed quitters from 
those who were not confirmed as quitters.
Material and methods
Our study used baseline data from a cluster randomized controlled trial prior to 
randomization and before implementing a brief smoking cessation counseling intervention. 
Women were eligible for the study if they attended one of 21 prenatal clinic clusters and 
delivered in one of 10 public hospitals in the Province of Buenos Aires, Argentina, or one of 
two hospitals in Montevideo, Uruguay, during October 2011–May 2012 (5). Within 12 h 
after delivery, trained interviewers asked eligible women two questions about their smoking 
status, and women who self-reported quitting smoking during pregnancy were asked to 
provide a saliva sample by chewing on the cotton swab insert from a Salivette® (Sarstedt, 
Newton, NC, USA). A longer survey was administered to women later, but within 48 h after 
delivery, to collect more detailed information regarding demographics, smoking patterns 
during pregnancy, and secondhand smoke exposure. Information about parity was also 
abstracted from medical charts. The study was approved by the ethics committees of all 
participating hospitals, the Ministry of Health of the Province of Buenos Aires, Argentina, 
the Center for Medical Education and Clinical Research “Norberto Quirno,” Buenos Aires, 
Argentina, the Faculty of Medicine, University of the Republic, Montevideo, Uruguay, as 
well as the Center for Diseases Control, Atlanta, and the Tulane University in New Orleans 
institutional review boards (USA).
The saliva samples were stored in a refrigerator at the hospital for up to 1 month, transferred 
to a central freezer in each country, and shipped with dry ice to the Centers for Disease 
Control and Prevention laboratory in Atlanta, for analysis. Salivary cotinine was measured 
by high-performance liquid chromatography atmospheric-pressure chemical ionization 
tandem mass spectrometry (LC APCI MS/MS) using a modification of a method that has 
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been described previously (6,7). Briefly, a 0.5-mL aliquot of the saliva sample was spiked 
with a deuterium-labeled cotinine-d3 internal standard and then applied to a basified, 
supported liquid extraction column and extracted with methylene chloride. All samples were 
analyzed on an AB Sciex API 4000 tandem mass spectrometer (http://discover.absciex.com/
mass-spectrometer), with the heated nebulizer installed, by measuring selected quantitation 
and confirmation transition ions in the multiple reaction monitoring mode in comparison 
with a standard curve. The limit of detection was 0.015 ng/mL.
Of 3427 women enrolled in the randomized controlled trial at baseline, 441 (12.9%) were 
included in the analysis if they self-reported smoking cessation upon learning of the 
pregnancy (spontaneous quitter) or sometime later during the pregnancy (later quitter) and 
consented to provide saliva. Women with missing data for demographic, clinical or 
secondhand smoke exposure were excluded from analyses [range: 0.2% (home smoking 
ban) to 6.4% (parity)]. We calculated the percentage and 95% confidence intervals of 
women with biochemically confirmed smoking cessation overall and by selected 
characteristics. It should be noted that the baseline data were collected prior to the clusters 
being randomized and before implementing the intervention; thus treatment condition would 
not have an effect on nondisclosure rates and was not assessed.
Although the precise cut-off point to determine active smoking in pregnant women is 
unknown, we considered a cut-off point of >10 ng/mL to determine active smoking, as this 
point was recommended by a scientific committee convened by the Society for Research on 
Nicotine and Tobacco (8). The recommended 10 ng/mL cut-off point for pregnant women is 
lower than the one used for the general population (>15 ng/mL), as nicotine is metabolized 
and cotinine is cleared faster during pregnancy (8). To assess possible misclassification due 
to varying levels of secondhand exposure, sensitivity analyses were conducted using two 
additional cut-off points. These points were determined from non-pregnant population-based 
studies conducted in countries with low secondhand smoke exposure (>3 ng/mL) and with 
extensive secondhand smoke exposure (>15 ng/mL) (3,9).
We compared biochemically confirmed quitters with those who were not confirmed quitters. 
Analyses were conducted using SURVEYFREQ and SURVEYREG procedures in SAS 
version 9.3 to account for the clustered study design. Wald chi-squared test for 
independence (p-value <0.05) was used to assess differences in characteristics of women 
who were biochemically confirmed quitters to those who were not confirmed as quitters.
Results
Most of the women in the sample were aged 20–29 years old (72.9%), married or partnered 
(82.8%), had incomplete secondary education (79.9%), were unemployed (72.7%), and had 
previous live births (62.0%). On average, women attended eight prenatal care visits and 
reported smoking a mean of 12 cigarettes/day prior to pregnancy.
Overall, 67.1% (296/441) of postpartum women in the sample said that they quit when they 
learned of the pregnancy (spontaneous quitter), and 32.9% (145/441) said that they quit 
sometime later during the pregnancy (later quitter) (Table 1). Based on the cotinine cut-off 
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point of >10 ng/mL, 10.0% (44/441) of total self-reported quitters had evidence of continued 
smoking. A significantly higher proportion of later quitters had evidence of continued 
smoking (17.2%) compared with spontaneous quitters (6.4%) (p = 0.01). Using a lower cut-
off point of >3 ng/mL, 17.0% of self-reported quitters, 12.2% of spontaneous quitters, and 
26.9% of later quitters had evidence of continued smoking. Using a higher cut-off point of 
>15 ng/mL, 8.4% of self-reported quitters, 5.7% of spontaneous quitters, and 13.8% of later 
quitters had evidence of continued smoking.
Women with evidence of continued smoking (cotinine >10 ng/mL), compared with women 
without evidence of continued smoking, were more likely to be a later quitter (56.8% and 
30.2%, respectively), had prior live births (77.5% and 60.3%) and allowed smoking in the 
home (59.1% and 38.9%) (Table 2). There were no differences seen for maternal age, 
marital status, education, work status, whether the woman’s partner or other household 
member smoked, frequency that the woman was around other smokers, number of cigarettes 
smoked per day before pregnancy, or receipt of provider advice to quit. However, the 
sample size had limited power to test differences in proportions of women according to 
these characteristics.
Discussion
The overall nondisclosure rate (10%) found in pregnant women in our study countries, and 
one based on a lower cut-off point (17%), was lower than has been reported in high-income 
countries. For example, in the USA and the UK it was estimated using biochemical 
verification that a quarter of pregnant women who smoke do not disclose their smoking 
status (3,4). This difference in nondisclosure rates may be a result of heightened awareness 
of the dangers of smoking during pregnancy and prevailing societal stigma against prenatal 
smokers (1). In our study countries, smoking is still very prevalent among the general 
population (10) and also among health care providers. In Argentina, about a third of 
physicians smoke (11), and 10% of physicians in Uruguay reported smoking (12). As a 
result, the lower nondisclosure rate in our study may suggest that pregnant smokers may feel 
less stigmatized and therefore do not hide their true smoking status. However, as strong 
tobacco control efforts are implemented in these countries and knowledge of the health 
effects of prenatal smoking becomes more prevalent, it may be necessary to evaluate 
whether nondisclosure rates change in pregnant women over time in these countries.
This study also shows that the nondisclosure rate for women who quit later in pregnancy 
was significantly higher than the nondisclosure rate for spontaneous quitters among women 
attending prenatal care. In addition, characteristics associated with non-disclosure included 
higher parity and smoking allowed in the house, consistent with risk factors for continued 
prenatal smoking (13).
The study had several limitations. First, the precise cut-off point to identify smoking among 
pregnant women is unknown, and varies by secondhand smoke exposure. Pregnant women 
metabolize nicotine and clear cotinine faster than non-pregnant women (8). We applied 
generally accepted cotinine cut-off points, which may underestimate nondisclosure rate. We 
also utilized a lower and higher cut-off point to account for varying secondhand smoke 
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exposure in our study countries. Secondly, as cotinine can be cleared within 2 days (8), our 
study protocol required that the saliva sample be obtained from women as soon as possible 
after delivery, but no later than 12 h after delivery. However, our estimates of nondisclosure 
could be underestimated if the duration of labor and delivery exceeded 48 h from a woman’s 
last cigarette. Thirdly, our sample size had limited power and was not planned to test 
differences in nondisclosure. Finally, these results may not be generalizable to women with 
characteristics different from those in the 21 prenatal clusters sampled.
In conclusion, one in 10 postpartum women in our study who self-reported smoking 
cessation during pregnancy had cotinine levels consistent with active smoking. In view of 
this, prenatal care providers should be trained to conduct effective and non-judgmental 
assessment of tobacco use to encourage disclosure (14).
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Table 1
Comparison of self-reported smoking cessation during pregnancy with saliva cotinine cut-points of 10 ng/mL, 
including sensitivity analyses with cut-points of 3 and 15 ng/mL.
Saliva cotinine
Self-report ≤10 ng/mL >10 ng/mL Total p-value*
Spontaneous quitter 93.6, 90.5–96.6 (277) 6.4, 3.4–9.4, (19) 67.1, 59.4–74.8 (296) 0.0106
Later quitter 82.8, 76.5–89.0 (120) 17.2, 11.0–23.5 (25) 32.9, 25.2–40.6 (145)
Total 90.0, 87.2–92.9 (397) 10.0, 7.1–12.8 (44) 100.0 (441)
≤3 ng/mL >3 ng/mL
Spontaneous quitter 87.8, 84.2–91.5 (260) 12.2, 8.5–15.8 (36) 67.1, 59.4–74.8 (296) 0.0149
Later quitter 73.1, 63.8–82.4 (106) 26.9, 17.6–36.2 (39) 32.9, 25.2–40.6 (145)
Total 83.0, 79.3–86.7 (296) 17.0, 13.3–20.7 (75) 100.0 (441)
≤15 ng/mL >15 ng/mL
Spontaneous quitter 94.3, 91.2–97.4 (279) 5.7, 2.6–8.8 (17) 67.1, 59.4–74.8 (296) 0.0531
Later quitter 86.2, 79.4–93.0 (125) 13.8, 7.0–20.6 (20) 32.9, 25.2–40.6 (145)
Total 91.6, 88.7–94.6 (404) 8.4, 5.4–11.3 (37) 100.0 (441)
Values are expressed as %, 95% CI and (n).
*
Wald chi-square test for independence was used to assess differences in characteristics of women who were biochemically confirmed quitters and 
those who were not confirmed as quitters.
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Table 2
Characteristics of women by biochemical confirmation of smoking cessation during pregnancy.
Saliva cotinine ≤10 ng/mL
(n = 397)
Saliva cotinine >10 ng/mL
(n = 44) p-value*
Self-reported quit status
 Spontaneous quitter 69.8, 62.2–77.3 (277) 43.2, 25.4–61.0 (19) 0.0106
 Later quitter 30.2, 22.7–37.8 (120) 56.8, 39.0–74.6 (25)
Maternal age (years)
 <20 19.1, 15.6–22.5 (74) 14.0, 0.1–27.8 (6) 0.7407
 20–29 72.4, 68.9–75.9 (281) 76.7, 61.8–91.7 (33)
 ≥30 8.5, 5.8–11.2 (33) 9.3, 0.3–18.3 (4)
Marital status
 Married or partnered 83.7, 80.0–87.4 (329) 74.4, 56.4–92.4 (32) 0.3217
 Not married 16.3, 12.6–20.0 (64) 25.6, 7.6–43.6 (11)
Highest level of education
 Completed primary school or less 31.0, 24.8–37.1 (122) 36.4, 23.4–49.3 (16) 0.0735
 Incomplete secondary school 50.0, 42.3–57.7 (197) 34.1, 17.7–50.4 (15)
 Completed secondary or higher 19.0, 11.0–27.0 (75) 29.5, 17.2–41.9 (13)
Work status
 Employed or student 27.3, 17.9–36.7 (104) 26.8, 8.2–45.4 (11) 0.9379
 Unemployed 72.7, 63.3–82.1 (277) 73.2, 54.5–91.8 (30)
Parity
 0 39.7, 33.9–45.5 (148) 22.5, 9.8–35.2 (9) 0.0446
 ≥1 60.3, 54.5–66.1 (225) 77.5, 64.8–90.2 (31)
Average no. prenatal care visits 8.2, 7.8–8.6 (386) 7.5, 6.4–8.6 (42) 0.1904
Smoking allowed in home
 Yes 38.9, 30.2–47.5 (154) 59.1, 47.6–70.6 (26) 0.0136
 No 61.1, 52.5–69.8 (242) 40.9, 29.4–52.4 (18)
Partner or other household member smokes
 Yes 70.4, 66.3–74.4 (273) 78.6, 60.0–97.1 (33) 0.3598
 No 29.6, 25.6–33.7 (115) 21.4, 2.9–40.0 (9)
How often around smokers
 Never 17.4, 11.3–23.6 (68) 7.0, 0–15.3 (3) 0.1042
 Rarely 23.6, 19.9–27.3 (92) 16.3, 0.8–31.8 (7)
 Sometimes 43.3, 39.1–47.5 (169) 46.5, 27.4–65.6 (20)
 Always 15.6, 12.5–18.8 (61) 30.2, 21.2–39.3 (13)
Average no. cigarettes smoked per day before pregnancy 10.3, 9.5–11.1 (387) 12.3, 10.1–14.4 (44) 0.1405
No. cigarettes smoked per day before pregnancy
 <10 46.0, 39.4–52.6 (178) 34.1, 12.0–56.1 (15) 0.2249
 10–19 32.0, 24.0–40.1 (124) 27.3, 5.5–49.1 (12)
 ≥20 22.0, 17.7–26.2 (85) 38.6, 19.1–58.2 (17)
Received provider advice to quit smoking
 Yes 63.2, 55.8–70.6 (249) 63.6, 49.4–77.8 (28) 0.9580
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Saliva cotinine ≤10 ng/mL
(n = 397)
Saliva cotinine >10 ng/mL
(n = 44) p-value*
 No 36.8, 29.4–44.2 (145) 36.4, 22.2–50.6 (16)
Values are expressed as % or mean, 95% CI and (n).
Sample size varied by each item due to missing values.
*
Wald chi-square test for independence was used to assess differences in characteristics of women who were biochemically confirmed quitters and 
those who were not confirmed as quitters.
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